Cart
sales@molnova.com
Home - Products - Neuroscience - Gamma-secretase - Demcizumab

Demcizumab

CAS No. 1243262-17-0

Demcizumab( —— )

Catalog No. M36721 CAS No. 1243262-17-0

Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 565 Get Quote
5MG 886 Get Quote
10MG 1416 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Demcizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
  • Description
    Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
  • In Vitro
    Cell Viability AssayCell Line:PDTALL13 (patient-derived T-ALL 13) cell Concentration:0, 0.5, 1, 5, 10, 20, 40, 80 μg/mL Incubation Time:1 or 2 or 3 days Result:Dose-dependently inhibited cell viability.
  • In Vivo
    Animal Model:KRASWT and KRASMT CRC xenografts Dosage:10 mg/kg, together with Irinotecan (HY-16562) (7.5 mg/kg) Administration:Intraperitoneal injection (i.p.), once a week Result:Resulted in tumor regression at day 20.
  • Synonyms
    ——
  • Pathway
    Neuroscience
  • Target
    Gamma-secretase
  • Recptor
    Gamma-secretase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1243262-17-0
  • Formula Weight
    145.65 (kDa)
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res. 2014 Dec 15;20(24):6295-303. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Rovalpituzumab

    Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs).

  • (20S)-Protopanaxadio...

    (20S)-Protopanaxadiol (20-Epiprotopanaxadiol), an apoptosis inducer, is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponin.

  • RO7185876

    RO7185876 is a selective gamma secretase modulator, which can be used in the study of Alzheimer's disease.

Sign In Join Free